<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Buzas D</submitter><funding>European Research Council</funding><funding>Wellcome Trust</funding><funding>Biotechnology and Biological Sciences Research Council</funding><pagination>342-351.e6</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7616808</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>32(3)</volume><pubmed_abstract>Adenovirus-derived nanoparticles (ADDomer) comprise 60 copies of adenovirus penton base protein (PBP). ADDomer is thermostable, rendering the storage, transport, and deployment of ADDomer-based therapeutics independent of a cold chain. To expand the scope of ADDomers for new applications, we engineered ADDobodies, representing PBP crown domain, genetically separated from PBP multimerization domain. We inserted heterologous sequences into hyper-variable loops, resulting in monomeric, thermostable ADDobodies expressed at high yields in Escherichia coli. The X-ray structure of an ADDobody prototype validated our design. ADDobodies can be used in ribosome display experiments to select a specific binder against a target, with an enrichment factor of ∼10&lt;sup>4&lt;/sup>-fold per round. ADDobodies can be re-converted into ADDomers by genetically reconnecting the selected ADDobody with the PBP multimerization domain from a different species, giving rise to a multivalent nanoparticle, called Chimera, confirmed by a 2.2 Å electron cryo-microscopy structure. Chimera comprises 60 binding sites, resulting in ultra-high, picomolar avidity to the target.</pubmed_abstract><journal>Structure (London, England : 1993)</journal><pubmed_title>Engineering the ADDobody protein scaffold for generation of high-avidity ADDomer super-binders.</pubmed_title><pmcid>PMC7616808</pmcid><funding_grant_id>221708</funding_grant_id><funding_grant_id>BB/R000484/1</funding_grant_id><funding_grant_id>202904/Z/16/Z</funding_grant_id><funding_grant_id>106115/Z/14/Z</funding_grant_id><funding_grant_id>206181/Z/17/Z</funding_grant_id><funding_grant_id>210701/Z/18/Z</funding_grant_id><funding_grant_id>221708/Z/20/Z</funding_grant_id><funding_grant_id>834631</funding_grant_id><pubmed_authors>Capin J</pubmed_authors><pubmed_authors>Yadav SKN</pubmed_authors><pubmed_authors>Berger I</pubmed_authors><pubmed_authors>Gautam G</pubmed_authors><pubmed_authors>Sessions RB</pubmed_authors><pubmed_authors>Bufton JC</pubmed_authors><pubmed_authors>Toelzer C</pubmed_authors><pubmed_authors>Buzas D</pubmed_authors><pubmed_authors>Gupta K</pubmed_authors><pubmed_authors>Sun H</pubmed_authors><pubmed_authors>Garzoni F</pubmed_authors><pubmed_authors>Schaffitzel C</pubmed_authors><pubmed_authors>Borucu U</pubmed_authors></additional><is_claimable>false</is_claimable><name>Engineering the ADDobody protein scaffold for generation of high-avidity ADDomer super-binders.</name><description>Adenovirus-derived nanoparticles (ADDomer) comprise 60 copies of adenovirus penton base protein (PBP). ADDomer is thermostable, rendering the storage, transport, and deployment of ADDomer-based therapeutics independent of a cold chain. To expand the scope of ADDomers for new applications, we engineered ADDobodies, representing PBP crown domain, genetically separated from PBP multimerization domain. We inserted heterologous sequences into hyper-variable loops, resulting in monomeric, thermostable ADDobodies expressed at high yields in Escherichia coli. The X-ray structure of an ADDobody prototype validated our design. ADDobodies can be used in ribosome display experiments to select a specific binder against a target, with an enrichment factor of ∼10&lt;sup>4&lt;/sup>-fold per round. ADDobodies can be re-converted into ADDomers by genetically reconnecting the selected ADDobody with the PBP multimerization domain from a different species, giving rise to a multivalent nanoparticle, called Chimera, confirmed by a 2.2 Å electron cryo-microscopy structure. Chimera comprises 60 binding sites, resulting in ultra-high, picomolar avidity to the target.</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Mar</publication><modification>2026-06-21T03:10:02.632Z</modification><creation>2025-04-21T21:48:52.284Z</creation></dates><accession>S-EPMC7616808</accession><cross_references><pubmed>38198950</pubmed><doi>10.1016/j.str.2023.12.010</doi></cross_references></HashMap>